Vienomics (因合生物)

Shenzhen, China

Vienomics is a pioneer in early-stage cancer detection and the first Chinese company to commercialize genomic liquid biopsy testing services for cancer screening. Vienomics began with a simple idea – to detect cancer early and proactively treat cancer at a curable stage. Being on the cutting edge of transforming cancer diagnosis is more than an ambition. The work we do every day saves tens of thousands of real lives and families. Our proprietary digital sequencing technology with unprecedented breadth and depth enables us to get a precise picture of the individual genomic alterations associated with development and progression of cancer. At Vienomics, we believe it is our responsibility to deliver the most reliable and accurate results. That’s why we established strict quality system with the international leading level. We are collaborating with top community and academic medical centers to conduct clinical studies to confirm the clinical validity and utility of our products.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Vienomics (因合生物) on @MedStartr Today #EarlyCancerDetection #CancerScreening #Cancer #PrecisionMedicineDiagnostics #MedMo #MedStartrVentures

https://www.medstartr.ai/s/J468Guw7oKE

Get Involved in Vienomics (因合生物)

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2016
Website: vienomics.com

Disease Areas

Early Cancer Detection Cancer Screening

Technologies

Liquid BiopsyGenomicsGenetic TestingScreening Technology

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Vienomics (因合生物)?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.